NCT03148132View on ClinicalTrials.gov

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

August 30, 2018

Study Completion Date

August 30, 2018

Conditions
Retinopathy of Prematurity Both EyesRetinal DiseasePremature BirthEye Diseases
Interventions
DRUG

Bevacizumab Injection

0.5mg/0.02 mL

DRUG

Ranibizumab Ophthalmic

0.25mg/0.025 mL

Trial Locations (1)

78170

"Hospital Central Dr. Ignacio Morones Prieto", San Luis Potosí City

All Listed Sponsors
collaborator

"Hospital Central Dr. Ignacio Morones Prieto"

OTHER

lead

Universidad Autonoma de San Luis Potosí

OTHER

NCT03148132 - VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP | Biotech Hunter | Biotech Hunter